Replimune Group Inc

Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3. The firm's Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin A. Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

RP1: Registration-directed randomized controlled Phase 2 clinical trial of RP1 in combination with cemiplimab-rwlc (Libtayo®) in cutaneous squamous cell carcinoma (CSCC) underway

Replimune Provides 2019 Year End Corporate Update and Reviews Expected 2020 Milestones

WOBURN, Mass., Jan.  09, 2020  (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the evolution of the responsibilities within its executive leadership team, reflecting the progress the Company has made into later stage clinical development and as it prepares for future commercialization.

Replimune Announces the Evolution of its Management Team as it Advances Through Later Stage Clinical Development and Prepares for Commercialization

WOBURN, Mass., Dec.  09, 2019  (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the expansion of its executive team with the appointment of Jean M. Franchi as Chief Financial Officer. Ms. Franchi will lead the Company’s financial strategy as Replimune continues to advance its pipeline of next-generation oncolytic immuno-gene therapies for the treatment of cancer.

Replimune Strengthens Executive Team with the Appointment of Jean Franchi as Chief Financial Officer

Energy Transfer LP Unit

Kadmon Hlds

Did you know that the GuruFocus All-in-One Screener can be used to find insider trades from a specific period of time or a certain range of value?

Largest Insider Trades of the Week (Nov 22)

BOSTON, Nov.  12, 2019  (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced a proposed public offering of up to 5,000,000 shares of its common stock. All shares in the offering will be offered by Replimune. In addition, Replimune intends to grant the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock from Replimune on the same terms and conditions.

Replimune Announces  Proposed Public Offering

Data demonstrate RP1 alone and combined with Opdivo® is well tolerated with anti-tumor efficacy in target tumor types

 Replimune Presents Initial Clinical Data with RP1 that Strongly Supports Expansion of Clinical Programs in Melanoma and Cutaneous Squamous Cell Carcinoma (CSCC)

Replimune’s second product candidate to enter the clinic is an Immulytic™ that expresses an anti-CTLA-4 antibody-like protein Replimune’s second product candidate to enter the clinic is an Immulytic™ that expresses an anti-CTLA-4 antibody-like protein

Replimune Announces First Patient Enrolled in Phase 1 Clinical Trial of RP2 Alone and in Combination with Opdivo® in Advanced Cancer Patients

Abstract highlights initial data from Phase 1 part of Phase 1/2 clinical trial of RP1 alone and in combination with Opdivo® (nivolumab) Abstract highlights initial data from Phase 1 part of Phase 1/2 clinical trial of RP1 alone and in combination with Opdivo® (nivolumab)

Replimune Announces Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Shares have lost 4% of their value since my April article.

Replimune Group: Updates To Thesis, Data Approaching In Q4

Share price performance is relatively flat since July 2018 IPO.

Replimune: Unchanged Since IPO, Run-Up Expected Into Clinical Data

Replimune Group Inc (NASDAQ: REPL)'s lead asset is expected to quickly pass through development and clear the FDA hurdle, according to Wedbush. 

Replimune's Lead Asset Likely To Clear Regulatory Hurdle, Wedbush Says In Bullish Initiation

News for Replimune Group Inc Stock (REPL)